David A Solomon
Overview
Explore the profile of David A Solomon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
200
Citations
6189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez Almaraz E, Guerra G, Al-Adli N, Young J, Dada A, Quintana D, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf024.
PMID: 40051658
Background: Isocitrate dehydrogenase (IDH)-mutant astrocytomas represent the most frequent primary intraparenchymal brain tumor in young adults, which typically arise as low-grade neoplasms that often progress and transform to higher grade...
2.
Horbinski C, Solomon D, Lukas R, Packer R, Brastianos P, Wen P, et al.
JAMA Oncol
. 2024 Dec;
PMID: 39724142
Importance: Molecular techniques, including next-generation sequencing, genomic copy number profiling, fusion transcript detection, and genomic DNA methylation arrays, are now indispensable tools for the workup of central nervous system (CNS)...
3.
Lucas C, Al-Adli N, Young J, Gupta R, Morshed R, Wu J, et al.
Neuro Oncol
. 2024 Nov;
27(1):89-105.
PMID: 39560080
Background: Despite recent advances in the biology of IDH-wildtype glioblastoma, it remains a devastating disease with median survival of less than 2 years. However, the molecular underpinnings of the heterogeneous...
4.
Geng H, Mo S, Mo S, Chen L, Ballapuram A, Tsang M, et al.
Blood Adv
. 2024 Nov;
9(5):1117-1131.
PMID: 39536287
The determination of the genetic subtypes of primary central nervous system lymphoma (PCNSL) and their relationship to differential chemoimmunotherapeutic response has not been established. There is a particular need for...
5.
Rodriguez A, Ahluwalia M, Bettegowda C, Brem H, Carter B, Chang S, et al.
Front Oncol
. 2024 Oct;
14:1471257.
PMID: 39376983
Implementation of standardized protocols in neurooncology during the surgical resection of brain tumors is needed to advance the clinical treatment paradigms that use tissue for diagnosis, prognosis, bio-banking, and treatment....
6.
Nazzal E, Reddy R, Solomon D, Hughes J, Rooney J, Fourman M, et al.
Arch Bone Jt Surg
. 2024 Jun;
12(6):400-406.
PMID: 38919741
Objectives: This study aimed to compare short-term outcomes following Total Shoulder Arthroplasty (TSA) and Humeral Head Resurfacing (HHR) in patients with glenohumeral osteoarthritis (GHOA). Methods: A retrospective analysis included patients...
7.
Lucas C, Mirchia K, Seo K, Najem H, Chen W, Zakimi N, et al.
Nat Genet
. 2024 May;
56(6):1121-1133.
PMID: 38760638
Intratumor heterogeneity underlies cancer evolution and treatment resistance, but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all...
8.
Mathur R, Wang Q, Schupp P, Nikolic A, Hilz S, Hong C, et al.
Cell
. 2024 Jan;
187(2):446-463.e16.
PMID: 38242087
Treatment failure for the lethal brain tumor glioblastoma (GBM) is attributed to intratumoral heterogeneity and tumor evolution. We utilized 3D neuronavigation during surgical resection to acquire samples representing the whole...
9.
Appin C, Hong C, Suwala A, Hilz S, Mathur R, Solomon D, et al.
Neuro Oncol
. 2023 Dec;
26(4):640-652.
PMID: 38141254
Background: The TERT promoter mutation (TPM) is acquired in most IDH-wildtype glioblastomas (GBM) and IDH-mutant oligodendrogliomas (OD) enabling tumor cell immortality. Previous studies on TPM clonality show conflicting results. This...
10.
Hadad S, Gupta R, Oberheim Bush N, Taylor J, Villanueva-Meyer J, Young J, et al.
Acta Neuropathol
. 2023 Dec;
147(1):3.
PMID: 38079020
Glioblastoma is a clinically and molecularly heterogeneous disease, and new predictive biomarkers are needed to identify those patients most likely to respond to specific treatments. Through prospective genomic profiling of...